Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Earnings for Trevi Therapeutics, Inc. (TRVI)
Earnings in 2023 (TTM): $-29,097,000
According to Trevi Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-29,097,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Trevi Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-29,097,000 | $-29,065,000 |
| 2022 | $-29,188,000 | $-29,152,000 |
| 2021 | $-33,961,000 | $-33,940,000 |
| 2020 | $-32,776,000 | $-32,758,000 |
| 2019 | $-26,068,000 | $-26,050,000 |
| 2018 | $-20,669,000 | $-20,545,000 |
| 2017 | $-12,886,000 | $-12,860,000 |
| 2016 | $-11,095,000 | $-11,087,000 |